SCHEMBL85706

SCHEMBL85706

CCOC(=O)c1cc2cc(C)ccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 1.00
KDM4E B2RXH2 3/20 1.00
ALDH1A1 P00352 3/20 1.00
HPGD P15428 3/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
HSD17B10 Q99714 1/20 1.00
NPC1 O15118 3/20 0.72
LMNA P02545 2/20 0.72
HTT P42858 1/20 0.72
L3MBTL1 Q9Y468 1/20 0.72
HRH3 Q9Y5N1 1/20 0.72
MMP13 P45452 8/20 0.70
MMP2 P08253 6/20 0.70
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
GLA P06280 1/20 0.67
GAA P10253 1/20 0.67
MAPT P10636 1/20 0.67
ATM Q13315 1/20 0.67
MMP14 P50281 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30994860 1.00 RAB9A (1.00) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL31310280 0.90 RAB9A (0.81) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5623372 0.88 KDM4E (0.78) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL31310346 0.87 ALDH1A1 (0.77) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL68923 0.86 HRH3 (0.84) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL829213 0.86 KDM4E (0.76) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL829242 0.86 KDM4E (0.76) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL8870168 0.86 KDM4E (0.75) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL31310255 0.86 RAB9A (0.75) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL940171 0.85 KDM4E (0.74) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113831275-A Indole-substituted 6-phenylindenoindole derivative and preparation method and application thereof 上海兆维科技发展有限公司 2021-12-24 CN claimed
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US claimed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US claimed
CN-104030971-B A kind of method synthesizing carbazole alkaloid karapinchamine A 浙江大学 2016-12-07 CN claimed
CN-104030971-A Method for synthesizing carbazole alkaloid karapinchamine A UNIV ZHEJIANG 2014-09-10 CN claimed
US-12570679-B2 STAT3 protein degraders REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-03-10 US disclosed
US-12522623-B2 Small molecule STAT protein degraders REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-01-13 US disclosed
EP-4634156-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-10-22 EP disclosed
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-26 US disclosed
US-12168009-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-12-17 US disclosed
WO-2024238598-A2 STAT DEGRADERS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2024-11-21 WO disclosed
WO-2024125624-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-06-20 WO disclosed
CN-1276790-A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them SANOFI SA (FR) 2000-12-13 CN disclosed
EP-1003504-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS AstraZeneca UK Limited (GB) 2000-05-31 EP disclosed
WO-1999007351-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed
US-5440046-A Angiotensin antagonist, hypotensive agent HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-08 US disclosed
US-5428043-A Tricyclic-cyclic amines as novel cholinesterase inhibitors PFIZER INC. (US) 1995-06-27 US disclosed
US-5350751-A Hypotensive agents HOECHST AKTIENGESELLSCHAFT (DE) 1994-09-27 US disclosed
EP-0441517-A2 Tricyclic amines as novel cholinesterase inhibitors PFIZER INC. (US) 1991-08-14 EP disclosed
US-4137313-A ANTICOAGULANTS, ANTIPHLOGISTIC AGENTS BOEHRINGER INGELHEIM GMBH (DE) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS XPA, MEP1A, EED RAB9A 3179/4885KDM4E 280/4885ALDH1A1 107/4885
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells XPA, MEP1A, EED RAB9A 3179/4885KDM4E 280/4885ALDH1A1 107/4885
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 RAB9A 888/4885KDM4E 2973/4885ALDH1A1 3524/4885
US-12570679-B2 STAT3 protein degraders STAT3, JAK2, IL6ST RAB9A 988/4885KDM4E 251/4885ALDH1A1 1666/4885
US-12168009-B2 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, SCNN1B, SLC26A4 RAB9A 888/4885KDM4E 2973/4885ALDH1A1 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.